Coherus Biosciences | CHRS - Capitaux Propres Et Réserves





Capitaux Propres Et Réserves Changement Date
AbbVie USD -3.27B 628M 2025-12
Acadia Pharmaceuticals USD 917.27M 94.89M 2025-09
Akebia Therapeutics USD 32.61M 8.98M 2025-12
ALKERMES USD 1.82B 85.86M 2025-12
Alnylam Pharmaceuticals USD 789.18M 555.28M 2025-12
Amarin USD 459.28M 387K 2025-12
Amgen USD 8.66B 961M 2025-12
Baxter International USD 6.13B 1.11B 2025-12
Biogen USD 18.21B 573.5M 2025-09
BioMarin Pharmaceutical USD 6.09B 30.29M 2025-12
Bristol-Myers Squibb USD 18.55B 1.06B 2025-09
Coherus Biosciences USD 61.01M 26.76M 2025-12
Eli Lilly USD 26.54B 2.74B 2025-12
Fujifilm JPY 3.72T 230.16B 2025-12
Gilead Sciences USD 22.62B 1.16B 2025-12
Ironwood Pharmaceuticals USD -264.16M 44M 2025-09
Merck USD 51.85B 2.79B 2025-09
Myriad Genetics USD 368M 4.8M 2025-12
Pacira USD 693.11M 34.1M 2025-12
Perrigo USD 2.94B 1.51B 2025-12
Pfizer USD 92.8B 4.11B 2025-09
PTC Therapeutics USD -205.31M 49.56M 2025-12
Regeneron Pharmaceuticals USD 31.26B 299.1M 2025-12
Sarepta Therapeutics USD 1.14B 179.5M 2025-12
Teva Pharmaceutical Industries USD 7.91B 664M 2025-12
Vertex Pharmaceuticals USD 18.67B 1.35B 2025-12
Xencor USD 635.59M 10.27M 2025-12
Zoetis USD 3.33B 2.07B 2025-12